6955 Stock Overview
A development stage company, manufactures medical instruments and solutions for the male infertility market. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Bonraybio Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$140.00 |
| 52 Week High | NT$162.50 |
| 52 Week Low | NT$71.04 |
| Beta | 0 |
| 1 Month Change | 1.08% |
| 3 Month Change | 3.70% |
| 1 Year Change | 91.44% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 86.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6955 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -5.1% | -3.0% | -0.9% |
| 1Y | 91.4% | -0.03% | 27.7% |
Return vs Industry: 6955 exceeded the TW Biotechs industry which returned 2.4% over the past year.
Return vs Market: 6955 exceeded the TW Market which returned 28.1% over the past year.
Price Volatility
| 6955 volatility | |
|---|---|
| 6955 Average Weekly Movement | 3.6% |
| Biotechs Industry Average Movement | 4.2% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.0% |
Stable Share Price: 6955 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6955's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | n/a | bonraybio.com |
Bonraybio Co., Ltd., a development stage company, manufactures medical instruments and solutions for the male infertility market. The company provides LensHooke X12 PRO semen analysis systems; and LensHooke X1 PRO semen quality analyzers. It also offers consumables, such as CS3 semen test slides; CA0/CA1 sperm separation solutions; and CS1 semen test cassettes.
Bonraybio Co., Ltd. Fundamentals Summary
| 6955 fundamental statistics | |
|---|---|
| Market cap | NT$2.75b |
| Earnings (TTM) | NT$0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs 6955 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6955 income statement (TTM) | |
|---|---|
| Revenue | NT$0 |
| Cost of Revenue | NT$0 |
| Gross Profit | NT$0 |
| Other Expenses | NT$0 |
| Earnings | NT$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 6955 perform over the long term?
See historical performance and comparison